Lantern Pharma Inc. Form 8-K Summary
Business Context and Reporting Period
Lantern Pharma Inc. (LTRN), a Delaware corporation, filed this Current Report on Form 8-K on August 14, 2026. The filing announces the upcoming release of financial results for the second quarter ended June 30, 2026.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document serves as a notification of the release of these metrics rather than containing the data itself.
Material Changes
No material changes or comparative financial data are disclosed within this filing text. The document references a press release (Exhibit 99.1) and a presentation (Exhibit 99.2) for detailed operating results.
Guidance, Outlook, and Risks
The Company scheduled a conference call and live webinar on August 14, 2026, to discuss financial and operating results. The filing includes standard disclaimers stating that the press release and presentation are not deemed "filed" under Section 18 of the Exchange Act and are not incorporated by reference unless specifically cited.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual Q2 2026 financial figures.
- Examine Exhibit 99.2 (Presentation) for management commentary and operational updates.
- Verify the date and time of the conference call to access live management discussion.
- Confirm that the financial data in the exhibits aligns with the Company's historical reporting standards.